top of page

Featured Publication

Thrombospondin 1 missense alleles induce extracellular matrix protein aggregation and TM dysfunction in congenital glaucoma.

Published in 2022, this JCI paper describes our discovery of a novel mutation in Thrombospondin 1 (THBS1) that causes congenital glaucoma, which is the leading cause of blindness in newborns.

Fu#500 TEM Optic nerve_F500_20220405028.tif

Publication List


Fu H, Siggs OM, Knight LS, Staffieri SE, Ruddle JB, Birsner AE, Collantes ER, Craig JE, Wiggs JL, D'Amato RJ. Thrombospondin 1 missense alleles induce extracellular matrix protein aggregation and TM dysfunction in congenital glaucoma.
J Clin Invest. 2022 Dec 1;132(23)

Peng DW, Lan CL, Dong LQ, Jiang MX, Xiao H, D'Amato RJ, Chi ZL. Anti-angiogenic properties of microRNA-29a in preclinical ocular models. Proc Natl Acad Sci U S A. 2022 Nov 8;119(45)

Khajavi M, Zhou Y, Schiffer AJ, Bazinet L, Birsner AE, Zon L, D'Amato RJ. Identification of Basp1 as a novel angiogenesis-regulating gene by multi-model system studies. FASEB J. 2021 May;35(5)

Adini A, Adini I, Grad E ,Tal Y, Danenberg HD, Kang PM, Matthews BD, D’Amato RJ. The Prominin-1-Derived Peptide Improves Cardiac Function Following Ischemia. Int. J. Mol. Sci. 2021, 22, 5169.

Bai J, Khajavi M, Sui L, Fu H, Tarakkad Krishnaji S, Birsner AE, Bazinet L, Kamm RD, D'Amato RJ. Angiogenic responses in a 3D micro-engineered environment of primary endothelial cells and pericytes. Angiogenesis. 2021 Feb;24(1):111-127.


Steinberg E, Fluksman A, Zemmour C, Tischenko K, Karsch-Bluman A, Brill-Karniely Y, Birsner AE, D'Amato RJ, Benny O. Low dose amiodarone reduces tumor growth and angiogenesis. Sci Rep. 2020 Oct 22;10(1):18034.

Bai J, Fu H, Bazinet L, Birsner AE, D'Amato RJ. A Method for Developing Novel 3D Cornea-on-a-Chip Using PrimarMurine Corneal Epithelial and Endothelial Cells. Front Pharmacol. 2020 Apr 28;11:453.

Guan JT, Li XX, Peng DW, Zhang WM, Qu J, Lu F, D'Amato RJ, Chi ZL. MicroRNA-18a-5p Administration Suppresses Retinal Neovascularization by Targeting FGF1 and HIF1A. Front Pharmacol. 2020 Mar 10;11:276. 


Chi ZL, Adini A, Birsner AE, Bazinet L, Akula JD, D'Amato RJ. PR1P ameliorates neurodegeneration through activation of VEGF signaling pathway and remodeling of the extracellular environment. Neuropharmacology. 148: 96-106, 2019


Wu H, Rahman HNA, Dong Y, Liu X, Lee Y, Wen A, To KHT, Xiao L, Birsner AE, Bazinet L, Wong S, Song K, Brophy ML, Mahamud MDR, Chang B, Cai X, Pasula S, Kwak S, Yang W, Bischoff J, Xu J, Bielenberg DR, Dixon JB, D'Amato RJ, Srinivasan RS, Chen H. Epsin deficiency promotes lymphangiogenesis through regulation of VEGFR3 degradation in diabetes. Journal of Clinical Investigation. 128(9):4025-4043, 2018


Adini A, Adini I, Chi ZL, Derda R, Birsner AE, Matthews BD, D'Amato RJ. A novel strategy to enhance angiogenesis in vivo using the small VEGF-binding peptide PR1P. Angiogenesis. 20(3):399-408, 2017
Khajavi M, Zhou Y, Birsner AE, Bazinet L, Rosa Di Sant A, Schiffer AJ, Rogers MS, Krishnaji ST, Hu B, Nguyen V, Zon L, D'Amato RJ. Identification of Padi2 as a novel angiogenesis-regulating gene by genome association studies in mice. PLoS Genet. 13(6):e1006848, 2017


Abramov E, Cassiola F, Schwob O, Karsh-Bluman A, Shapero M, Ellis J, Luyindula D, Adini I, D'Amato RJ, Benny O.  Cellular mechanism of oral absorption of solidified polymer micelles. Nanomedicine. 11(8):1993-2002, 2015

Adini I, Adini A, Bazinet L, Watnick RS, Bielenberg DR, D'Amato RJ.  Melanocyte pigmentation inversely correlates with MCP-1 production and angiogenesis-inducing potential.  FASEB J. 29(2):662-70, 2015


Adini I, Ghosh K, Adini A, Benny O, Connor K, Bazinet L, Birsner AE, Bielenberg D, D'Amato RJ.  Melanocytes Regulate the Angiogenic Microenvironment via Fibromodulin.  J Clin Invest  124(1):425-36, 2014
Birsner AE, Benny O, D'Amato RJ.  The corneal micropocket assay: a model of angiogenesis in the mouse eye.  J Vis Exp. (90), 10.3791/51375, 2014
Hasegawa E, Sweigard H, Husain D, Olivares AM, Chang B, Smith KE, Birsner AE, D'Amato RJ, Michaud NA, Han Y, Vavvas DG, Miller JW, Haider NB, Connor KM.  Characterization of a spontaneous retinal neovascular mouse model.  PLoS One.  9(9):e106507, 2014


Adini A, Adini I, Ghosh K, Benny O, Pravda E, Hu R, Luyindula D, D'Amato RJ.  The stem cell marker prominin-1/CD133 interacts with vascular endothelial growth factor and potentiates its action.  Angiogenesis 16(2):405-16, 2013

Xu H, Zhang T, Man GC, May KE, Becker CM, Davis TN, Kung AL, Birsner AE, D'Amato RJ, Wong AW, Wang CC.  Vascular endothelial growth factor C is increased in endometrium and promotes endothelial functions, vascular permeability and angiogenesis and growth of endometriosis.  Angiogenesis. 16(3):541-51, 2013

Rogers MS, Adini I, McBride AF, Birsner AE, D'Amato RJ.  The albino mutation of tyrosinase alters ocular angiogenic responsiveness.  Angiogenesis. 16(3):639-46, 2013

Yoshimura T, Benny O, Bazinet L, D'Amato RJ.  Suppression of autoimmune retinal inflammation by an antiangiogenic drug.  PLoS One. 8(6):e66219, 2013


Peterson JE, Zurakowski D, Italiano JE Jr, Michel LV, Connors S, Oenick M, D'Amato RJ, Klement GL, Folkman J.   VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients.  Angiogenesis. 15(2):265-73, 2012.

Rogers MS, Boyartchuk V, Rohan RM, Birsner AE, Dietrich WF, D'Amato RJ. The classical pink-eyed dilution mutation affects angiogenic responsiveness.  PloS One. 7(5):e35237, 2012


Erba P, Ogawa R, Ackermann M, Adini A, Miele LF, Dastouri P, Helm D, Mentzer SJ, D'Amato RJ, Murphy GF, Konerding MA, Orgill DP.  Angiogenesis in wounds treated by microdeformational wound therapy.  Ann Surg. 253(2):402-9, 2011

Becker CM, Beaudry P, Funakoshi T, Benny O, Zaslavsky A, Zurakowski D, Folkman J, D'Amato RJ, Ryeom S.  Circulating endothelial progenitor cells are up-regulated in a mouse model of endometriosis.  Am J Pathol. 178(4):1782-91, 2011

Xu H, Becker CM, Lui WT, Chu CY, Davis TN, Kung AL, Birsner AE, D'Amato RJ, Wai Man GC, Wang CC.  Green tea epigallocatechin-3-gallate inhibits angiogenesis and suppresses vascular endothelial growth factor C/vascular endothelial growth factor receptor 2 expression and signaling in experimental endometriosis in vivo.  Fertil Steril.  96(4):1021-8,



Erba P, Miele LF, Adini A, Ackermann M, Lamarche JM, Orgill BD, D'Amato RJ, Konerding MA, Mentzer SJ, Orgill DP.   A morphometric study of mechanotransductively induced dermal neovascularization. Plast Reconstr Surg.  128(4):288e-299e, 2011


Benny O, Nakai K, Yoshimura T, Bazinet L, Akula JD, Nakao S, Hafezi-Moghadam A, Panigrahy D, Pakneshan P,  D’Amato RJ.  Broad spectrum antiangiogenic treatment for ocular neovascular diseases. PLoS One. 5(9): e12515, 2010
Fainaru O, Almog N, Nakai K,  Montoya-Zavala M, Abollahi A, D’Amato RJ, and Ingber D.   Tumor growth and angiogenesis are dependent on the presence of immature dendritic cells.   FASEB Journal  24(5):1411-8, 2010


Adini A, Fainaru O, Udagawa T, Connor KM, Folkman J, D'Amato RJ.  Matrigel cytometry: a novel method for quantifying angiogenesis in vivo. J Immunol Methods. 342(1-2):78-81, 2009

Nakai K, Rogers M, Baba T, Funakoshi T, Birsner A, Luyindula D, and D’Amato  RJ.  Genetic loci that control the size of laser-induced choroidal neovascularization.  FASEB Journal  23(7):2235-43, 2009


Fainaru O, Adini A, Benny O, Adini I, Short S, Bazinet L, Nakai K, Pravda E, Hornstein MD, D'Amato RJ, Folkman J.  Dendritic cells support angiogenesis and promote lesion growth in a murine model of endometriosis. FASEB Journal. Feb;22(2):522-9, 2008

Becker CM, Rohwer N, Funakoshi T, Cramer T, Bernhardt W, Birsner A, Folkman MJ, D’Amato RJ.  2-Methoxyestradiol Inhibits Hypoxia Inducible Factor-1α and Suppresses Growth of Lesions in a Mouse Model of Endometriosis. Am J Pathol  172(2):534-44, 2008

Nakai K, Fainaru O, Bazinet L, Pakneshan P, Benny O, Pravda E, Folkman J, D'Amato RJ.  Dendritic cells augment choroidal neovascularization. Invest Ophthalmol Vis Sci. 49(8):3666-70, 2008

Pakneshan P, Birsner A, Adini I, Becker C, D’Amato RJ.  Differential Suppression of Vascular Permeability and Corneal Angiogenesis by Non-Steroidal Anti-Inflammatory Drugs.  Invest Ophthalmol Vis Sci.  49(9):3909-13, 2008

Benny O, Fainaru O, Adini A, Cassiola F, Bazinet, Adini I, Pravda E, Koirala S, Corfas G, D'Amato RJ and Folkman MJ.    An orally delivered small-molecule formulation with antiangiogenic and anticancer activity.  Nature Biotech.  26(7):799-807, 2008

Fainaru O, Adini I, Benny O, Bazinet L, Pravda E, D'Amato R, Folkman J.  Doxycycline induces membrane expression of VE-cadherin on endothelial cells and prevents vascular hyperpermeability.  FASEB Journal. 22(10):3728-35, 2008


Udagawa T, Birsner A, Wood M, Schaefer BC, D’Amato RJ.  Chronic suppression of angiogenesis following radiation exposure is independent of hematopoietic reconstitution.    Cancer Res. 1;67(5):2040-5, 2007

Rogers MS, Christensen KA, Birsner AE, Short SM, Wigelsworth DJ, Collier RJ, D'Amato RJ. Mutant anthrax toxin B moiety (protective antigen) inhibits angiogenesis and tumor growth. Cancer Res.  Oct 15;67(20):9980-5, 2007


Becker CM, Wright RD, Satchi-Fainaro R, Funakoshi T, Folkman J, Kung AL, D’Amato RJ.  A novel noninvasive model of endometriosis for monitoring the efficacy of antiangiogenic therapy. Am J Pathol. 168(6):2074-84, 2006

Becker CM, Sampson DA, Short SM, Javaherian K, Folkman J, D’Amato RJ.  Short synthetic endostatin peptides inhibit endothelial migration in vitro and endometriosis in a mouse model. Fertil Steril. 85(1):71-7, 2006

Udagawa T, Puder M, Wood M, Schaefer BC, D’Amato RJ.  Analysis of tumor-associated stromal cells using SCID GFP transgenic mice: contribution of local and bone marrow-derived host cells.  FASEB Journal.  20(1):95-102, 2006

Funakoshi T, Birsner AE, D’Amato RJ.  Antiangiogenic effect of oral 2-methoxyestradiol on choroidal neovascularization in mice.  Exp Eye Res. 83(5):1102-7, 2006


Shaked Y, Bertolini F, Man S, Rogers M, Cervi D., Foutz T, Rawn K, Voskas D, Dumont D, Ben-David Y, Lawler J, Henkin J, Huber J, Hicklin D, D’Amato RJ, and Kerbel RS.  Genetic heteogeneity of the vascular phenotype parallels angiogenesis: Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell   7(1):101-11, 2005

Efstathiou JA, Sampson DA, Levine Z, Rohan RM, Zurakowski D, Folkman J, D’Amato RJ, Rupnick MA.  Nonsteroidal antiinflammatory drugs differentially suppress endometriosis in a murine model.  Fertil Steril. 83(1):171-81, 2005

Wood M, Udagawa T, Hida Y, D’Amato RJ.   X-linked dominant growth suppression of transplanted tumors in C57BL/6J-scid mice. Cancer Res. 1;65(13):5690-5, 2005

Becker CM, Sampson DA, Rupnick MA, Rohan RM, Efstathiou JA, Short SM, Taylor GA, Folkman MJ and D’Amato RJ.  Endostatin inhibits the growth of endometriotic lesions while not affecting fertility. Fertil Steril. 84 Suppl 2:1144-55, 2005


Rogers MS, Rohan RM, D’Amato RJ.  Genetic loci that control the angiogenic response to basic fibroblast growth factor.   FASEB Journal 18(10):1050-1059, 2004.

Yen L, Svendsen J, Lee JS, Gray JT, Magnier M, Baba T, D’Amato RJ, Mulligan RC.  Exogenous control of mammalian gene expression through modulation of RNA self-cleavage. Nature  23;431(7007):471-6, 2004.


Kisker O, Onizuka S, Becker CM, Fannon M, Flynn E, D’Amato RJ, Zetter B, Folkman J, Ray R, Swamy N, Pirie-Shepherd S.   Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. Neoplasia 5(1):32-40, 2003

Rogers M, Rohan R, Birsner A, D’Amato RJ.  Genetic loci that control vascular endothelial growth factor induced angiogenesis.  FASEB Journal 17(14):2112-4, Sept 2003


D’Amato RJ, Lentzsch S, Anderson KC, Rogers MS.  Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma. Semin Oncol  28(6):597-601, 2002

Hazzard TM, Rohan RM, Molskness TA, Fanton JW, D’Amato RJ, Stouffer RL.  Injection of antiangiogenic agents into the macaque preovulatory follicle: disruption of corpus luteum development and function. Endocrine. 17(3):199-206, 2002

Lentzsch S, Rogers MS, LeBlanc R, Birsner AE, Shah JH, Treston AM, Anderson KC, D’Amato RJ.   S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice. Cancer Res  62(8):2300-5, 2002

Udagawa T, Fernandez A, Folkman J, D’Amato RJ.  Persistence of microscopic human cancers in mice: Alterations in the angiogenic balance accompanies loss of dormancy.  FASEB Journal  16:1361-70, 2002


Fernandez A, Udagawa T, Scwesinger C, Beecken W, Gerte E, McDonnell T, D’Amato RJ  Angiogenic potential of prostate carcinoma cells overexpressing bcl-2. J Nat Cancer Inst  93(3) 33-38, 2001

Schwesinger C, Yee C, Rohan R, Joussen A, Fernandez A, Meyer T,  Poulaki V, Ma J,‡ Redmond TM, Liu S, Adamis A, D’Amato RJ.  Intrachoroidal Neovascularization in Transgenic Mice Overexpressing Vascular Endothelial Growth Factor in the Retinal Pigment Epithelium. Amer J Pathol  158(3) 1-11, 2001

Kuo C, Farnebo F, Yu E, Christofferson R, Swearingen R, Carter R, Yuan J, Kamihara J, Flynn E, D’Amato RJ, Folkman F, Mulligan R.  Comparative efficacy of adenovirus-encoded antiangiogenic proteins. Proc Nat Acad Sci USA  98(8) 4605-4610, 2001

Gupta AR, Dejneka NS, D’Amato RJ, Yang Z, Syed N, Maguire AM, Bennett J.   Strain-dependent anterior segment neovascularization following intravitreal gene transfer of basic fibroblast growth factor (bFGF). J Gene Med 3(3) 252-9, 2001

Stechschulte SU, Joussen AM, von Recum HA, Poulaki V, Moromizato Y, Yuan J, D’Amato RJ, Kuo C, Adamis AP.   Rapid ocular angiogenic control via naked DNA delivery to cornea. Invest Ophthalmol Vis Sci  42(9):1975-1979 , 2001

Kisker O, Becker CM, Prox D, Fannon M, D’Amato R, Flynn E, Fogler WE, Sim BK, Allred EN, Pirie-Shepherd SR, Folkman J.  Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res  61(20):7669-74, 2001


Rohan RM, Fernandez A, Udagawa T, Yuan J and D’Amato RJ.  Genetic heterogeneity of angiogenesis in mice. FASEB Journal 14(7):871-6, 2000

Udagawa T, Yuan J, Panigrahy D, Shah J, D’Amato RJ.  Cytochalasin E, an epoxide containing aspergillus-derived fungal metabolite, inhibits angiogenesis and tumor growth. J Pharmacol Exp Ther  294(2):421-7, 2000.

Fishman SJ, Feins NR, D’Amato RJ, Folkman J.  Thalidomide for Crohn's disease. Gastroenterology 119(2):596, 2000


Verheul HMW, Panigraphy D, Yuan J, D’Amato RJ.  Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumor growth in rabbits. Brit J Cancer   79(1) 114-118, 1999

Arbiser JL, Panigrathy D, Klauber N, Rupnick M, Flynn E, Udagawa T, D’Amato RJ.  The antiangiogenic agents TNP-470 and 2-methoxyestradiol inhibit the growth of angiosarcoma in mice. J Am Acad Dermatol 40(6 Pt 1):925-9, 1999

Verheul HMW, Panigrahy D, Flynn E, Pinedo HM and D’Amato RJ.  Treatment of the Kassabach Merrit syndrome with pegylated recombinant human megakaryocyte growth and development factor in mice: elevated platelet counts, prolonged survival and tumor growth inhibition. Pediatric Res 46(5):562-5, 1999

Fishman SJ, Feins NR, D’Amato RJ, Folkman J.  Long term remission of Chrohn’s disease treated with thalidomide. Angiogenesis 3:201-4, 1999


Pinedo HM, Verheul HM, D’Amato RJ, Folkman J.  Involvement of platelets in tumour angiogenesis. Lancet  352(9142):1775-7, 1998


Klauber N, Parangi S, Flynn E, Hamel E, D’Amato RJ.  Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res  57:81-86, 1997

Kenyon B, Browne F, D’Amato RJ.  Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res  64: 971-978, 1997

Klauber N, Rohan R, Flynn E, D’Amato RJ. Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-1470. Nature Med  3(4): 443-446, 1997

Punglia R, Lu M, Hsu J, Kuroki M, Tolentino M, Keough K, Levy AP, Levy NS, Goldberg MA, D’Amato RJ, Adamis AP.  Regulation of vascular endothelial growth factor expression by insulin-like growth factor-1. Diabetes  46(10):1619-26, 1997


Hamel E, Lin CM, Flynn E, D’Amato RJ.   Interactions of 2-methoxyestradiol, an endogenous mammalian metabolite, with unpolymerized tubulin and with tubulin polymers. Biochem  35: 1304-1310, 1996

Loughnan M, Chatziftefanou K, Flynn E, Adamis T, Shing Y, D’Amato R, Folkman J.   Experimental corneal neovascularization using sucralfate and bFGF. Aust. & New Zeal J Ophthal 24(3):289-295. 1996

Klauber N, Browne F, Anand-Apte B, D’Amato RJ.  A new activity of spironolactone: inhibition of angiogenesis in vitro and in vivo. Circulation  94(10):2566-2571, 1996

Kenyon BM, Voest EE, Chen CC, Flynn E, Folkman J, D'Amato RJ. A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci. Jul;37(8):1625-32. 1996


Voest EE, Kenyon BM, O’Reilly MS, Truitt G, D’Amato RJ, Folkman J.   Interleukin 12 inhibits angiogenesis in vivo. J Nat Cancer Inst  8:581-586, 1995

Klauber N, Parangi S, Hamel E, D’Amato RJ.  Growth suppression of human breast carcinoma in vivo and inhibition of angiogenesis in vivo by the endogenous estrogen metabolite 2-methoxyestradiol. Surg. Forum  46: 470-472, 1995

1994 and earlier

Hodgson Smith LE, Wesolowski E, McLellan A, Kostyk S, D’Amato RJ, Sullivan RT, D'Amore PA.   Oxygen induced retinopathy in the mouse. Invest Ophthalmol Vis Sci.  35(1):101-119, 1994

D’Amato RJ, Loughnan MS, Flynn E, Folkman J.   Thalidomide is an inhibitor of angiogenesis. Proc Nat Acad Sci USA  91: 4082-4085, 1994

D’Amato RJ, Lin CM, Flynn E, Folkman J Hamel E.   2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site.  Proc Nat Acad Sci USA  91: 3964-3968, 1994

D’Amato RJ, Wesolowski E, Hodgson Smith LE.  Microscopic visualization of the retina with high-molecular weight fluorescein-labeled dextrans in the mouse.  Microvasc Res 46: 135-142, 1993

D’Amato RJ,  Miller NR,  Fine SL,  Enger C,  Quinlan P,  Elman MJ.   The effect of age and initial visual acuity on the systemic and visual prognosis of central retinal vein occlusion.  Aust & New Zeal J of Ophthal.  9(2):118-22, 1991

Janiri L, D’Amato R, Zieglgansberger W.  Dynorphin (1-17) reduces the inhibitory actions of mu and delta selective opioid agonists in cortical neurons of the rat in vivo. Neuroscience Letters 84: 79-83., 1987

D’Amato RJ Blue ME, Largent BL, Lynch DR, Ledbetter DJ, Molliver ME and Snyder SH.  Ontogeny of the serotonergic projection to rat neocortex: Transient expression of a dense innervation to primary sensory areas. Proc Nat Acad Sci USA  84: 4322-4326, 1987

D’Amato RJ, Benham DF and Snyder SH.  Characterization of the binding of MPP+ (N-methyl-4-phenyl-pyridine), the toxic metabolite of the Parkinsonian neurotoxin MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) to neuromelanin. Neurochem  48(2): 653-658, 1987

D’Amato RJ, Alexander GM, Schwartzman RJ, Kitt CA, Price DL and Snyder SH.  Neuromelanin:  a role in MPTP induced neurotoxicity. Life Sciences   40(8): 705-712, 1987

D’Amato RJ, Zweig RM, Whitehouse PJ, Wenk GL, Singer HS, Mayeaux R, Price DL and Snyder SH.  Aminergic systems in Alzheimer's disease and Parkinson's disease. Annals of Neurology  22:229-236, 1987

D’Amato RJ, Alexander GM, Schwartzman RJ, Kitt CA, Price DL and Snyder SH.   Chloroquine protection of MPTP treated monkeys implicates neuromelanin in Parkinsonian neurotoxicity. Nature  327: 324-326, 1987

D’Amato RJ, Largent BL, Snowman AM and Snyder, SH. Selective labeling of serotonin uptake sites in rat brain by [3H]citalopram contrasted to labeling of multiple sites by [3H]imipramine. J Pharm Exp Therap  242(1): 364-371, 1987

Snyder SH and D’Amato RJ.  MPTP:  a neurotoxin relevant to the pathophysiology of Parkinson's disease. Neurology  36:250-258, 1986

D’Amato RJ, Lipman ZP and Snyder, SH.  Selectivity of the Parkinsonian neurotoxin MPTP: toxic metabolite MPP binds to neuromelanin. Science  231:987-989, 1986

Javitch J, D’Amato R, Strittmatter S and Snyder SH.  Parkinsonism-inducing neurotoxin  MPTP:  Uptake of the metabolite by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA  82:2173-2177, 1985

Snyder SH and D’Amato RJ.  Predicting Parkinson's disease. Nature  317 (6034):198-199, 1985

D’Amato RJ and Holaday JW.  Multiple opiate receptors in endotoxic shock:  Evidence for delta involvement and mu-delta interactions in vivo. Proc Natl Acad Sci USA  81:2898-2901, 1984

Holaday JW, Pasternak GW, D’Amato RJ, Ruvio BA and Faden AI.  Naloxazone lacks therapeutic effects in endotoxic shock yet blocks the effects of naloxone. Eur J Pharm   89:293-296, 1983

Holaday J.W, D’Amato RJ, Ruvio B, Feurestein G and Faden AI.  Adrenalectomy blocks pressor response to naloxone in endotoxic shock:  Evidence for sympatho-medullary involvement. Circ Shock  11:201-210, 1983

Holaday JW and D’Amato RJ.  Multiple opiate receptors: Evidence for mu-delta binding site interactions in endotoxic shock. Life Sciences  33:703-706, 1983

Holaday JW and D’Amato RJ.  Thyrotropin releasing hormone (TRH) reverses endotoxic shock through both central sympatho-adrenal and peripheral actions. Circ Shock  10:260-261, 1983

Holaday JW, Ruvio BA, Robles LE, Johnson CE and D’Amato, RJ.   ICI M154,129, A putative delta antagonist reverses endotoxic shock without altering  morphine analgesia. Life Sciences  31:2209-2212, 1982

Holaday JW and D’Amato RJ.  Naloxone or TRH fails to improve neurologic deficits in gerbil models of "stroke". Life Sciences 31:385-392, 1982

Holaday JW and D’Amato RJ.  Naloxone in cerebral ischemia. Lancet i:1238-9, 1982

Holaday JW and D’Amato RJ.  Naloxone and ischemic neurologic deficits in the gerbil. Science  218:592-593, 1982

Holaday JW, D’Amato RJ and Faden, AI.  Thyrotropin releasing hormone improves cardiovascular function in experimental endotoxic and hemorrhagic shock. Science  213:216-218, 1981


bottom of page